Syntara Ltd: Interim data in Phase 2 study of SNT-5505 in myelofibrosis
Syntara Ltd: Notice of SNT-5505 Interim Phase 2 data webinar
Syntara Ltd: Trading Halt
Syntara Ltd: Response to ASX Price Query
Syntara Ltd: Pause in Trading
Syntara Ltd: Chair's Address to Shareholders
Syntara Ltd: Selected for oral presentation at ASH
Syntara Ltd: Quarterly Appendix 4C Cash Flow Report
Syntara Ltd: Change of Director's Interest Notice
Syntara Ltd: Appendix 4G - Key to Corporate Governance Disclosures
Syntara Ltd: Corporate Governance Statement 2024
Syntara Ltd: Proposed Issue of Securities to Chief Executive Officer
Syntara Ltd: Syntara appoints new CFO
Syntara Ltd: German MDS group awarded $2.5m grant for phase 2 MDS trial
Syntara Ltd: Phase 2 blood cancer trial fully recruited
Syntara Ltd: Quarterly Appendix 4C Cash Flow Report
Syntara Ltd: Trading Halt
Syntara Ltd: Change of Share Registry Management Services
Syntara Ltd: SNT to present in MST Access Hidden Gems Webinar
Syntara Ltd: Change of registry address notification